Published On: Wed, Oct 19th, 2016

Analyst Coverage: The Medicines Company (NASDAQ:MDCO)


Recently stock market analysts have updated their consensus ratings on shares of The Medicines Company (NASDAQ:MDCO).

Most recent broker ratings

10/06/2016 – The Medicines Company had its “outperform” rating reiterated by analysts at Leerink Swann.

10/06/2016 – The Medicines Company had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 43 price target on the stock.

08/15/2016 – The Medicines Company had its “buy” rating reiterated by analysts at Guggenheim. They now have a USD 55 price target on the stock.

07/12/2016 – The Medicines Company had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 48 price target on the stock.

05/06/2016 – Cowen began new coverage on The Medicines Company giving the company a “outperform” rating. They now have a USD 45 price target on the stock.

03/21/2016 – The Medicines Company had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 65 price target on the stock.

01/22/2016 – The Medicines Company had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 50 price target on the stock.

11/04/2015 – The Medicines Company had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 31 price target on the stock.

08/31/2015 – The Medicines Company had its “hold” rating reiterated by analysts at Citigroup.

08/31/2015 – The Medicines Company had its “market perform” rating reiterated by analysts at Oppenheimer.

07/06/2015 – The Medicines Company was upgraded to “buy” by analysts at Mizuho. They now have a USD 41 price target on the stock.

05/06/2015 – The Medicines Company was downgraded to “hold” by analysts at Zacks.

11/20/2014 – The Medicines Company was upgraded to “outperform” by analysts at Credit Suisse. They now have a USD 33 price target on the stock.

10/23/2014 – The Medicines Company had its “neutral” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 27 price target on the stock.

03/31/2014 – The Medicines Company was downgraded to “hold” by analysts at TheStreet.

The Medicines Company has a 50 day moving average of 38.09 and a 200 day moving average of 36.52. The stock’s market capitalization is 2.65B, it has a 52-week low of 27.50 and a 52-week high of 43.00.

The share price of the company (NASDAQ:MDCO) was up +5.98%, with a high of 39.00during the day and the volume of The Medicines Company shares traded was 2808562.

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company’s products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.